Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223103 · ClinicalTrials.gov registry record · Phase 1
Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma
A Phase 1 study of Glioblastoma, sponsored by Adilia Hormigo.
- Active
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT03223103 is a Phase 1 study of Glioblastoma that is active but no longer recruiting, run by Adilia Hormigo. The registered enrollment target is 13 participants, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03223103, a Phase 1 study of Glioblastoma, is active but no longer recruiting, sponsored by Adilia Hormigo.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields). The study is designed to determine whether this treatment combination is well tolerated and safe.
Conditions Studied
Interventions
- DRUG Poly-ICLC
- DEVICE Tumor Treating Fields
- BIOLOGICAL Peptides
Study Locations (1)
New York
- Albert Einstein College of Medicine - The Bronx
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2018-03-01 |
| Est. Completion | 2029-05-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03223103
The ClinicalTrials.gov registry entry for NCT03223103 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 109-participant average among 199 other Glioblastoma trials with a reported enrollment target (88% lower). The listed sponsor is Adilia Hormigo, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Poly-ICLC is the first listed.
NCT03223103 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03223103 about?
NCT03223103 is a clinical study titled "Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma". The purpose of this study is to use precision medicine in the form of a vaccine, a mutation-derived tumor antigen vaccine (MTA-based vaccine) in combination with standard care treatment of glioblastoma (GBM) and Tumor Treating Fields (TTFields). The study is designed to determine whether this treat...
What is the current status of trial NCT03223103?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2018-03-01. Estimated completion is 2029-05-12.
What conditions does trial NCT03223103 study?
This clinical trial studies the following conditions: Glioblastoma.
What interventions are being tested in trial NCT03223103?
The interventions under investigation include: Poly-ICLC (DRUG), Tumor Treating Fields (DEVICE), Peptides (BIOLOGICAL).
Who is sponsoring clinical trial NCT03223103?
This trial is sponsored by Adilia Hormigo, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03223103 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
RECRUITING · Phase 1
-
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
RECRUITING · Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
-
CUE-102 in Recurrent Glioblastoma
RECRUITING · Phase 1
-
Adenovirus Mediated Suicide Gene Therapy With Radiotherapy in Progressive Astrocytoma.
RECRUITING · Phase 1
-
Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.